Vir Biotechnology (VIR) said Thursday it has enrolled the first patient in a phase 3 study that will evaluate the efficacy and safety of its drug tobevibart in combination with elebsiran as a potential treatment for chronic hepatitis delta.
The trial is designed to provide the registrational data for submission to multiple regulatory agencies, the company said.
Chronic hepatitis delta is a severe inflammatory liver disease.
Shares were 0.5% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.